Recordati S.p.A. · MIL:REC

Recordati — 9M 2026 Earnings Presentation

17 slides from Recordati's earnings presentation, Nov 10, 2026

  1. Slide 1: First Nine Months 2026 Results

    FIRST NINE MONTHS 2026 R E S U LT S November 10th, 2026

  2. Slide 2: Financial Highlights for the First Nine Months 2026

    FINANCIAL HIGHLIGHTS FOR THE FIRST NINE MONTHS 2026 N E T A D J . N E T F R E E C A S H E B I T D A 2 R E V E N U E I N C O M E 3 F L O W 4 € 2,103.7 million € 801.1 million € 524.9 million € 459.8 million +7.5% +7.7% +6.4% +€ 63.0 million 9.4% like-for-like1 at CER 38.1% margin 25.0% margin ~1.6x (

  3. Slide 3: Rare Diseases: Continued Momentum Led by Isturisa

    RARE DISE ASES: CONTINUED MOMENTUM LED BY ISTURISA ® Revenue 9M 2026 vs 9M 2025 million Euro KEY HIGHLIGHTS Endocrinology +18.7% • Double-digit growth +18.7% vs PY (+21.3% like-for-like1 at CER) supported by continued momentum in Hema-Oncology Endocrinology and Hema-Oncology Metabolic 928.2 Endocrin

  4. Slide 4: Specialty & Primary Care: Resilient Performance Despite One-Off Headwinds

    S P E C I A LT Y & P R I M A R Y C A R E : R E S I L I E N T P E R F O R M A N C E D E S P I T E ONE-OFF HEADWINDS AND LOW COUGH & COLD SEASON Pharmaceutical Revenue 9M 2026 vs 9M 2025(1)(2) million Euro K E Y H I G H L I G H T S Cardiovascular +0.5% • Slight growth vs previous year, +0.5% or growth

  5. Slide 5: U.S. Growth Partially Offset by Select Regional Headwinds

    U . S . G R O W T H PA R T I A L LY O F F S E T B Y S E L E C T R E G I O N A L H E A D W I N D S (million euro) 9M 2026 9M 2025 Change % U.S. 486.9 371.5 31.1 Italy 230.1 259.8 (11.4) Spain 188.0 166.8 12.7 Russia, other CIS countries and Ukraine 139.1 126.5 10.0 France 129.3 137.7 (6.1) Germany 12

  6. Slide 6: Growth Across All Key Metrics

    GROWTH ACROSS ALL KEY METRICS % of % of (million Euro) 9M 2026 9M 2025 Change % revenue revenue Revenue 2,103.7 1,956.2 7.5 Gross Profit 1,501.7 71.4% 1,315.0 67.2% 14.2 Adjusted Gross Profit1 1,501.7 71.4% 1,377.5 70.4% 9.0 SG&A Expenses (583.9) (27.8%) (539.8) (27.6%) 8.2 R&D Expenses (274.8) (13.

  7. Slide 7: Higher Free Cash Flow Driven by Strong EBITDA Performance

    HIGHER FREE CASH FLOW DRIVEN BY STRONG EBITDA PERFORMANCE (million Euro) 9M 2026 9M 2025 Change EBITDA1 801.1 743.9 57.2 Movements in working capital (148.6) (137.5) (11.1) Changes in other assets & liabilities 58.1 8.6 49.5 Interest received/(paid) (75.5) (76.3) 0.8 Income tax paid (147.9) (121.5)

  8. Slide 8: FY 2026 Targets Confirmed, With Results Expected at Upper End of Ranges

    F Y 2 0 2 6 TA R G E T S C O N F I R M E D , W I T H R E S U LT S E X P E C T E D AT T H E UPPER END OF RANGES FY 2025 FY 2026 € million Actual Targets Outlook Net Revenue • Rare Diseases to deliver robust high-teen organic growth at CER, driven by Endocrinology (accelerating Isturisa® growth) and H

  9. Slide 9: Appendix

    APPENDIX

  10. Slide 10: Composition of Revenue: Diversified Portfolio and Footprint

    COMPOSITION OF REVENUE DIVERSIFIED PORTFOLIO AND FOOTPRINT Therapeutic Areas Geographic Total Revenue 9M 2026 Pharmaceutical Revenue 9M 2026* Rare Diseases 44.1% Metabolic Specialty & Primary Care Endocrinology Türkiye 2.0% USA (incl. Chemicals) 55.9% Portugal Hema-Oncology North Africa 2.7% Cardiov

  11. Slide 11: Main Products Net Revenue

    MAIN PRODUCTS NET REVENUE (million Euro) 9M 2026 9M 2025 Change % Specialty & Primary Care 1,135.5 1,129.9 0.5 Zanidip® and Zanipress® (lercanidipine+enalapril)1 142.6 144.1 (1.0) Eligard® (leuprorelin acetate) 104.6 95.5 9.5 Seloken®/Seloken® ZOK/Logimax® 75.3 81.3 (7.3) (metoprolol/metoprolol+felo

  12. Slide 12: Nine Months Results by Operating Segments

    N I N E M O N T H S 2 0 2 6 R E S U LT S BY O P E R AT I N G SEGMENTS Total Revenue 9M 2026 EBITDA1 9M 2026 Specialty and Specialty and Primary Care (incl. Primary Care (incl. Chemicals) Chemicals) 44.1% 48.9% Rare Diseases Rare Diseases 55.9% 51.1% Margin on Revenue: Rare Diseases: EBITDA1 42.2% Sp

  13. Slide 13: Leverage at ~1.6x EBITDA Driven by Strong Cash Generation

    L E V E R A G E AT ~ 1 . 6 x E B I T DA D R I V E N BY S T R O N G C A S H G E N E R AT I O N (million Euro) 30-Sep-26 31-Dec-25 Change Cash and cash equivalents 503.3 428.8 74.4 Short-term debts to banks and other lenders (14.5) (23.8) 9.4 Loans and leases - due within one year1 (620.6) (313.0) (30

  14. Slide 14: Nine Months Results – Adjusting Items

    N I N E M O N T H S 2 0 2 6 R E S U LT S – A D J U S T I N G I T E M S Reconciliation of Net income to EBITDA1 Summary of key items (million Euro) 9M 2026 9M 2025 % Net Income 407.1 326.3 24.8% Income Taxes 130.9 103.0 • Net FX losses of € 5.3 million in 9M 2026 vs € 10.9 million Financial (income)/

  15. Slide 15: R&D Program Update

    R & D P R O G R A M U P DAT E PROGRAM UPCOMING MILESTONE Osilodrostat • Hypertension caused by hypercortisolemia Trial initiated in August 2026 due to Cushing’s syndrome Pasireotide • Post-Bariatric Hypoglycemia (PBH)1 Phase 3 development plan to be finalized by year-end 2026 • High Risk relapsed/re

  16. Slide 16: Company Declarations, Disclaimers and Profile

    C O M PA N Y D E C L A R AT I O N S , D I S C L A I M E R S A N D PROFILE Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currentl

  17. Slide 17: Our purpose: Unlocking the full potential of life

    Our purpose: Unlocking the full potential of life. ~ RECORDATI

Recordati — 9M 2026 Earnings Presentation on 6ix